QPPV.COM KNOWLEDGE ASSESSMENT

EMA, European Commission, National Competent Authorities, CHMP, PRAC and CMDh: Who Does What?

Test your understanding of the concepts covered by EMA, European Commission, National Competent Authorities, CHMP, PRAC and CMDh: Who Does What?.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the principal institutional lesson from an urgent Union pharmacovigilance procedure such as an Article 107i procedure?

Urgency removes the need to distinguish scientific recommendations from legal implementation The procedure is intended for rapid Union-level safety assessment, with PRAC central to the scientific assessment and subsequent legal steps still determined by the framework The procedure transfers all national regulatory responsibilities permanently to EMA The procedure is used only for initial centralised marketing-authorisation applications

Question 2 of 10 A centrally authorised medicine requires a formal regulatory change following a pharmacovigilance assessment. Which sequence is the most conceptually accurate where the applicable legal framework requires all stages?

PRAC scientific assessment, subsequent CHMP consideration, and Commission legal action Commission scientific assessment, followed by PRAC licensing CMDh authorisation, followed by national inspection only National competent-authority decision, followed by EMA approval

Question 3 of 10 Why should a PRAC recommendation not automatically be treated as the final regulatory act?

PRAC does not assess safety evidence A recommendation is a scientific or regulatory output whose legal effect depends on the procedure and any subsequent legally required steps PRAC recommendations apply only to veterinary medicines All PRAC recommendations are advisory documents with no possible regulatory consequences

Question 4 of 10 A national competent authority supplies an expert who contributes to a centralised assessment. What does this demonstrate?

The centralised procedure has become a national authorisation procedure National authorities can contribute expertise to Union procedures while retaining their national regulatory responsibilities The expert independently determines the final marketing-authorisation decision EMA has delegated all legal decision-making to that national authority

Question 5 of 10 Which statement best captures the relationship between a medicine's original authorisation route and a later safety procedure?

The later safety procedure must always use the same institutional route as the original authorisation A nationally authorised medicine can never be subject to a Union pharmacovigilance procedure The original route and later safety route are related but may involve different bodies under the applicable legal basis A centralised product is supervised only by EMA throughout its lifecycle

Question 6 of 10 During an MRP, one participating Member State maintains a substantive concern that cannot be resolved. What is the most appropriate initial institutional interpretation?

The concern automatically becomes a centralised application CMDh may provide the relevant coordination framework, with possible escalation to a Union referral if statutory conditions are met PRAC must decide the issue because every MRP disagreement is pharmacovigilance-related The European Commission immediately grants or refuses the national authorisations

Question 7 of 10 Which body has the principal specialist mandate for assessing pharmacovigilance safety issues and risk-management questions at Union level?

CHMP CMDh PRAC The European Commission

Question 8 of 10 Which institutional pairing is most accurate?

PRAC — coordination of all MRP and DCP licensing disagreements CMDh — specialist pharmacovigilance signal assessment for human medicines CHMP — scientific assessment of human medicines within its legal mandate European Commission — routine operational inspection of every regulated site

Question 9 of 10 A newly detected safety signal is being reviewed. Which interpretation is most appropriate?

The signal automatically proves causality and requires immediate withdrawal The signal is an initial concern that must be assessed with the totality of available evidence The signal can be assessed only by the European Commission The signal is legally equivalent to a variation decision

Question 10 of 10 What is the best general description of EMA's role in the European medicines regulatory network?

A single EU regulator that replaces all national medicines authorities A Union agency that coordinates scientific expertise and provides regulatory infrastructure within its mandate A legislative body that creates pharmaceutical law independently of the Member States A national licensing authority acting on behalf of every Member State

EMA, European Commission, National Competent Authorities, CHMP, PRAC and CMDh: Who Does What?

Cookie Settings